Key Points
- Vaxcyte EVP Jim Wassil sold 1,334 shares for $79,399.68 at an average price of $59.52, reducing his position by 0.91%. The sale covered tax-withholding obligations tied to vested equity awards.
- Vaxcyte shares opened at $59.51, with a market capitalization of approximately $8.86 billion and a 12-month trading range of $30.81 to $65.00. The company reported quarterly EPS of negative $1.97, better than analysts’ expected loss of $2.06.
- Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $86.00, while institutional investors own 96.78% of the company’s stock.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 1,334 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68. Following the completion of the transaction, the executive vice president owned 145,435 shares of the company's stock, valued at approximately $8,656,291.20. This trade represents a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jim Wassil also recently made the following trade(s):
- On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
- On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total value of $212,340.39.
- On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total value of $121,185.00.
- On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.
Vaxcyte Price Performance
PCVX opened at $59.51 on Thursday. The stock's 50 day moving average price is $58.41 and its 200 day moving average price is $56.32. The stock has a market cap of $8.86 billion, a P/E ratio of -7.80 and a beta of 1.22. Vaxcyte, Inc. has a 12 month low of $30.81 and a 12 month high of $65.00.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same period last year, the business posted ($1.22) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current year.
Institutional Trading of Vaxcyte
A number of hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC lifted its holdings in shares of Vaxcyte by 143.4% in the second quarter. First Light Asset Management LLC now owns 345,157 shares of the company's stock valued at $20,064,000 after buying an additional 203,373 shares during the period. Engineers Gate Manager LP bought a new position in Vaxcyte during the second quarter valued at about $1,906,000. IFP Advisors Inc grew its holdings in Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company's stock worth $33,000 after acquiring an additional 236 shares during the period. Arizona State Retirement System grew its holdings in Vaxcyte by 4.3% during the second quarter. Arizona State Retirement System now owns 33,755 shares of the company's stock worth $1,962,000 after acquiring an additional 1,394 shares during the period. Finally, Nykredit A S bought a new stake in Vaxcyte in the second quarter worth about $280,000. Institutional investors own 96.78% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PCVX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Monday, July 6th. Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Vaxcyte has a consensus rating of "Moderate Buy" and an average price target of $86.00.
Check Out Our Latest Stock Analysis on PCVX
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
